|
| | | | | | | | | | | | | |
| Brand | Generic | Indication | MOA | Approval | IP | Economics | | | | Price | 333.78 | |
| Trikafta | elexacaftor/ivacaftor/tezacaftor | Cystic Fibrosis | | | | CFF/RPRX | | | | Shares | 257.5516 | Q123 |
| Symdeko | tezacaftor/ivacaftor | Cystic Fibrosis | | | | CFF/RPRX | | | | MC | 85965.57304799999 | |
| Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis | CFTR corrector | | | CFF/RPRX | | | | Cash | 11495.6 | Q123 |
| Kalydeco | ivacaftor | Cystic Fibrosis (G551D) | CFTR potentiator | | | Mitsubishi Tanabe in Japan? | | | | Debt | 0 | Q123 |
| | | | | | | | | | | EV | 74469.97304799999 | |
| | | | | | | | | | | | | |
| | | | | Phase | | | | | | | | |
| CTX001 | exagamglogene autotemcel | SCD/TDT | CRISPR | Filed | | CRSP | | | | | | |
| VX-548 | | Pain | Nav1.8 | III | | | | | | | | |
| VX-121 | vanzacaftor/tezacaftor/deutivacaftor | Cystic Fibrosis | | III | | | | | | | | |
| VX-147 | inaxaplin | APOL1 FSGS | | II/III | | | | Founded: 1989 | | | | |
| VX-880 | | T1D | cell therapy | I | | | | CMO: Carmen Bozic | | | | |
| VX-561 | deutivacaftor | Cystic Fibrosis | deuterated ivacaftor | III | | | | CSO: David Altshuler | | | | |
| VX-522 | | Cystic Fibrosis | mRNA | I | | MRNA | | Cell & Genetic Therapies: Bastiano Sanna | | | | |
| | | DMD | CRISPR | IND-enabling, IND in 2023 | | | | CEO: Reshma Kewalramani | | | | |
| | | Liver Disease | CRISPR | | | VERV | | | | | | |
| | | T1D | cell therapy+device | IND 2022 | | | | | | | | |
| VX-864 | | AATD | corrector | II | | | | | | | | |
| VX-634 | | AATD | corrector | I | | | | | | | | |
| | | | | | | | | | | | | |
| | | | 10/11/22: VX-634 IND approved. | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | 7/20/22: Verve collaboration for liver disease. $25m upfront. | | | | | | | | | |
| | | | 7/18/22: Q2 earnings date. | | | | | | | | | |
| | | | 7/11/22: To acquire Viacyte for $320m. | | | | | | | | | |
| | | | 7/5/22: VX-880 clinical hold lifted. | | | | | | | | | |
| | | | 6/11/22: EHA Congress CTX001 data | | | | | | | | | |
| | | | 6/10/22: EU CF Conference presentation for Trikafta | | | | | | | | | |
| | | | 6/8/22: investor conference | | | | | | | | | |
| | | | 6/8/22: inaxaplin FTD & PRIME designation | | | | | | | | | |
| | | | 6/6/22: VX-880 data at ADA | | | | | | | | | |
| | | | 6/2/22: CTX001 latebreaker accepted at EHA | | | | | | | | | |
| | | | 5/31/22: VX-880 data to be presented at ADA | | | | | | | | | |
| | | | 5/18/22: BOD addition | | | | | | | | | |
| | | | 5/17/22: Headquarters expansion | | | | | | | | | |
| | | | 5/17/22: Health equity donations | | | | | | | | | |
| | | | 5/5/22: Q1 results | | | | | | | | | |
| | | | 4/21/22: Q1 results day. | | | | | | | | | |
| | | | 4/20/22: Health Canada Trikafta approval for 6-11yo | | | | | | | | | |
| | | | 3/31/22: VX-548 Phase II data | | | | | | | | | |
| | | | 3/26/22: Australia Trikafta reimbursement agreement | | | | | | | | | |
| | | | 3/22/22: VX-147 Phase II/III initiation | | | | | | | | | |
| | | | 3/1/22: investor conference | | | | | | | | | |
| | | | 1/26/22: Q421 results | | | | | | | | | |